Agoracom Blog Home

Posts Tagged ‘THC’

Tetra Bio-Pharma Inc. Completes Pre-IND Meeting with FDA on PPP001 $TBP.ca

Posted by AGORACOM-JC at 10:21 AM on Monday, January 30th, 2017

Tbp large

  • Completed its pre-IND meeting with the USA Food and Drug Administration  for its PPP001 dried cannabis drug product
  • Meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research
  • FDA provided all the necessary guidance on the design of the Phase I trial in healthy volunteers and the overall product development program, including quality, nonclinical and the medical device, and on marketing requirements

OTTAWA, ONTARIO–(Jan. 30, 2017) – PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has completed its pre-IND meeting with the USA Food and Drug Administration (“FDA”) for its PPP001 dried cannabis drug product. The meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products (“DAAAP”), Center for Drug Evaluation and Research (“CDER”).

The FDA provided all the necessary guidance on the design of the Phase I trial in healthy volunteers and the overall product development program, including quality, nonclinical and the medical device, and on marketing requirements. Dr. Chamberland, M.Sc., Ph.D., Chief Scientific Officer and Regulatory Affairs, commented “We could not be more pleased, as the FDA guidance gave us a clear path to progress from early to late phase clinical development. Adhering to the US FDA regulations is part of Tetra Bio-Pharma’s dedication to the commercialization of Cannabis as a prescription controlled drug and the corporations plan to seek reimbursement by insurers for patients.”

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 689-0714

Tetra Bio-Pharma Inc. Announces New Appointment of Dr. Gilles Chamberland, M.D., FRCPC to its Scientific and Clinical Advisory Board $TBP.ca

Posted by AGORACOM-JC at 9:15 AM on Wednesday, January 11th, 2017

Tbp large

  • Announced the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board
  • Board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development

(TORONTO, ONTARIO  Jan. 11, 2017) – PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), is pleased to announce the nomination of Dr. Gilles Chamberland, MD, FRCPC, to its Scientific and Clinical Advisory Board. The board is comprised of experts in clinical research, pain management, cancer, and neurological product drug development. The nomination of Dr. Chamberland, M.D., to its Advisory Board will provide critical guidance on PPP’s clinical development program with regards to the safety of cannabis drug products and the potential mental health risks associated with the consumption of marijuana.

“Patient safety has been a driving force since the creation of PPP. The use of cannabis has been associated with several important safety issues including potential psychiatric-related events. As a company focused on creating scientific data these risks, as well as others, must be adequately assessed and quantified in a clinical environment. The addition of Dr. Gilles Chamberland, M.D., FRCPC, to our team of accomplished scientific and clinical experts will help us ensure that these potential adverse effects of consuming cannabis will be adequately assessed in our clinical development program and these potential risks will be appropriately communicated to both physicians and patients”, stated Dr. Guy Chamberland, Chief Scientific Officer and Regulatory Affairs.

ABOUT Dr. Gilles Chamberland

Dr. Gilles Chamberland, M.D., FRCPC – Director Professional Services, Medical Psychiatrist, Associate Professor, Department of Psychiatry, Institut Philippe-Pinel de Montréal, Université de Montréal.

Dr. Chamberland received a Bachelor of Law degree from the Université de Sherbrooke, a doctorate in medicine from the Université de Montréal, a diploma in psychiatry from the Université de Montréal, and a diploma of advanced studies in biological and medical ethics of the René Descartes University in Paris. In 2012, he earned the Distinguished Fellow from the Canadian Psychiatric Association and, by 2015 the American Psychiatric Association gave him the same professional recognition. He received a diploma in the subspecialty of Forensic Psychiatry in 2013 from the Royal College of Physicians and Surgeons of Canada. Dr. Chamberland has a vast experience in clinical management of patients suffering from various psychiatric conditions including marijuana induced-psychosis. He is also a well-known author and expert witness in the field on psychiatry.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Tetra Bio-Pharma Inc.
Andre Rancourt, Chief Executive Officer, or
Ryan Brown. VP Business Development and Communications, or
Andre Audet, Executive Chairman
(343) 689-0714
Investors@tetrabiopharma.com

More than $1 billion of marijuana sold in Colorado in 2016 $TBP.ca $MCOA.us

Posted by AGORACOM-JC at 4:23 PM on Tuesday, December 13th, 2016
Image result for cnn
  • Last year, the marijuana industry created 18,000 full-time jobs and generated $2.39 billion in economic activity in the state.
  • Recreational and medical cannabis shops have sold more than $1 billion of marijuana and related products so far in 2016, already surpassing last year’s total of $996,184,788

(CNN) It’s always 4/20 somewhere — at least in Colorado. The state’s marijuana shops have reached a massive new milestone: $1 billion in legal, regulated sales in the first 10 months of 2016.
Voters legalized marijuana in Colorado back in 2012, but the dispensaries didn’t open until 2014Last year, the marijuana industry created 18,000 full-time jobs and generated $2.39 billion in economic activity in the state.

And the boom is still growing. According to new data from the state’s Department of Revenue, recreational and medical cannabis shops have sold more than $1 billion of marijuana and related products so far in 2016, already surpassing last year’s total of $996,184,788.

Attorney Christian Sederberg, partner at Vicente Sederberg, played an integral part in Colorado’s Amendment 64, which legalized marijuana in the state. He is estimating that sales of pot will reach $1.3 billion by the end of this year, which could have a total economic impact of over $3 billion.
Designer marijuana boosts THC potency
Designer marijuana boosts THC potency 02:24
“This milestone continues to show that the cannabis industry in Colorado is an engine of growth for the economy, a job creator, and one of the biggest industries in the state,” Sederberg told CNN. “People were consuming cannabis before, but now they are buying it from tax-regulated businesses that are benefiting the economy. This has replaced an underground, illegal market.”
Sederberg says that marijuana has become one of the largest industries in Colorado, and certainly the fastest growing.
“From 2015 to 2016, there has been a 53% increase in retail sales and a 9% increase in medical sales,” he said. “Medical sales are growing at a much slower rate, but recreational sales will continue to grow in the double digits.”

All-time high

Marijuana sales in Colorado hit an all-time high in September 2016, generating $127.8 million, according to The Cannabist, a Colorado-based news site covering the industry. But October’s numbers are still sizable: Shops sold nearly $82.8 million of recreational cannabis and $35 million of medical marijuana.
Colorado has three different taxes on recreational marijuana — a standard 2.9% sales tax, a special 10% sales tax, and a 15% excise tax on wholesale transfers, which go towards schools. The state collected just over $6 million from the excise tax, bringing the yearly total to $49.7 million, The Cannabist tallied.
Of that, the first $40 million will go towards school construction projects, and any additional tax revenue from the excise tax will go directly to the state’s public school fund.
In this past election, California, Massachusetts, Nevada, and Maine all approved legal sales of recreational marijuana. Medical marijuana is now legal in more than half of US states. In total, marijuana sales could expand the national market to $21 billion by 2020. That is up from $5.7 billion last year and an expected $7.9 billion this year.
But in the eyes of the federal government, marijuana is still an illegal substance. The Drug Enforcement Administration classifies marijuana as a Schedule 1 drug, the same as heroin, LSD, and ecstasy.
Source: http://edition.cnn.com/2016/12/13/health/colorado-marijuana-sales-trnd/

Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001 $TBP.ca

Posted by AGORACOM-JC at 9:04 AM on Wednesday, November 23rd, 2016

Tbp large

  • Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit
  • FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

OTTAWA, ONTARIO–(Nov. 23, 2016) – PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF), is a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that the development of its smoked marijuana prescription drug is on schedule.

The Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration (“FDA“) had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit. The FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research (“CDER“) as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

The Company previously announced that it received a pre-IND (Investigational New Drug) acknowledgement and meeting request granted letter from the US FDA. This week, the company is submitting the information package required by FDA for the Type B pre-IND meeting in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research. According to Dr. G. Chamberland, Chief Science Officer, “As per FDA policies, the pre-IND information package is submitted to obtain guidance from FDA on the product development and marketing requirements for the smoked marijuana prescription drug combination product”. Dr. Chamberland further commented that this regulatory filing is part of PPP’s dedication to the commercialization of marijuana as a prescription controlled drug and the corporation’s plan to seek reimbursement by insurers for patients.

The Company has been working with Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects. PPP is using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry. Later this week the project team will be submitting the Phase I clinical protocol, and related documents, to the Institutional Review Board for review. If approved, Algorithme Pharma will subsequently submit the Clinical Trial Application to the Therapeutic Products Directorate of Health Canada for approval. In parallel, Algorithme Pharma will submit an application for exemption under section 56 of the Controlled Drugs and Substances Act for its planned research on healthy subjects.

The Company stated that, subsequent to a request for classification to the Medical Devices Bureau, Health Canada, the PPP001-titanium pipe that will be used in the clinical trial is a Class I medical device. Dr. Chamberland commented: “As a Class I medical device, the PPP001-titanium pipe does not require approval for use in the clinical trial”.

About PPP001-kit product

PPP001-kit product will be sold as two separate products packaged together in a single package and is comprised of the drug PPP001 and the device PPP001-titanium pipe. The drug component and device component will be linked together by the labelling of each component.

The product PPP001-kit, once approved, could be sold in pharmacies containing the prescription controlled drug PPP001, in a blister pack, and the PPP-titanium pipe device that will be used to generate the smoke to deliver the active ingredients by inhalation.

PPP001 drug pellet blisters and a fully assembled PPP-titanium pipe for combustion and inhalation of the generated smoke are required for therapy with PPP001 and are provided in the PPP001-kit.

Each blister of PPP001 drug pellet contains marijuana with a standardized amount of delta-9-tetrahydrocannibinol and cannibidiol. A single PPP001 drug pellet is pushed out of the blister by the patient and inserted into the PPP-titanium pipe.

In Other News:

The Company has received $227,738 in exercised warrants for November 2016.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Ryan Brown – VP Business Development and Communications
Andre Audet – Executive Chairman
Dr. Guy Chamberland – Chief Scientific Officer
(613) 421-8402

Tetra Bio-Pharma Achieves DTC Eligibility in the United States $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, November 16th, 2016

Tbp_large

  • Effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market
  • Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”.

OTTAWA, ONTARIO–(Nov. 16, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF) is pleased to announce that effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market.

Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors.

The Company’s common shares are listed for trading on the OTCPINK, a U.S. based securities trading system, under the symbol “GRPOF”. Tetra Bio-Pharma shares will continue to be traded on the Canadian Stock Exchange under its existing symbol “TBP”.

André Rancourt, Chief Executive Officer, commented, “We’re pleased to announce that our shares have become DTC eligible on the U.S. market and excited to bring our Company to the attention of the investment community in the U.S. We believe that GRPOF offers investors a unique opportunity to invest in a bio pharmaceutical cannabis company before entering clinical trials later this year.

In other company news

Website:

The Company is proud to announce that its website located at www.tetrabiopharma.com is now live. We encourage investors to sign up for news releases and notifications as more information is added to the website.

Industry Participation:

Dr. Guy Chamberland, Chief Scientific Officer and regulatory affairs, and Ryan Brown, co-founder and VP of Business Development, will be presenting at the World of Cannabis business summit in Las Vegas on November 16th 2016. Dr. Chamberland will be presenting as part of “the science of medical cannabis” program while Ryan Brown will be presenting at the “emerging brands investor pitch seminar” more info can be found at www.worldofcannabissummit.com.

Investor Relations:

The Company would like to inform investors that it has engaged Alpha Deal Group LLC, a New York based buy side analyst firm, to perform investor analysis for presentation to its investment network.

As released on November 9, 2016, via CFN (Cannabis Financial Network), the Company has engaged Cannabis Financial Network to increase its visibility in the United States retail investment market.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
Phone: (613) 421-8402

Ryan Brown
Co-founder and Director of Communications
Phone: (613) 421-8402

Andre Audet
Executive Chairman
Phone: (613) 421-8402

V-Love(tm) now available in London Drugs stores

Posted by AGORACOM-JC at 9:06 AM on Monday, June 29th, 2015

  • V-LoveTM is now available for purchase in 30 London Drugs stores and is to be in all 79 stores by Friday July 3rd
  • First shipment of V-LoveTM to the London Drugs main distribution facility in Richmond, BC was received and is in the process of being redistributed to all London Drugs stores across Western Canada

VANCOUVER, BC / June 29 2015 – Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) is pleased to announce V-LoveTM is now available for purchase in 30 London Drugs stores and is to be in all 79 stores by Friday July 3rd.

The first shipment of V-LoveTM to the London Drugs main distribution facility in Richmond, BC was received and is in the process of being redistributed to all London Drugs stores across Western Canada.

V-LoveTM can also be purchased online at Londondrugs.com for your personal convenience and can be shipped anywhere in Canada.

V-LoveTM is pH balanced specifically for women and provides lubrication and a moisturizing feeling to sooth vaginal dryness.


Click Image To View Full Size

V-LoveTM It all begins with desire…

“We are very pleased to be in a growing number of stores and look forward to growing our V-Love TM brand name,” stated President Robert McAllister.

About Enertopia

The Company’s mission is to empower people with a better way of living through healthy lifestyle choices in helping you live your life your way. Our core values of honesty, integrity, and commitment help to define our corporate practices and demonstrate our dedication in helping individuals whether they are encountering health issues based on age, diet or have suffered a traumatic physical, mental or an emotional event.

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President: (250) 765-6412

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation and sale of sexual creams and other items, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that V-Love TM will have any meaningful impact on the Company or the Company will be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Enertopia signed with London Drugs: V-Love ™ to be in stores soon

Posted by AGORACOM-JC at 8:34 AM on Monday, June 22nd, 2015

  • Announced it has signed with London Drugs Ltd. to sell V-LoveTM in all their 79 stores across Western Canada.
  • Soon to be available to the consumer in all London Drug Stores across Western Canada.
  • first shipment to the London Drugs main distribution facility in Richmond, BC has been received

VANCOUVER, BC / TheNewswire / June 22 2015 – Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) is pleased to announce it has signed with London Drugs Ltd. to sell V-LoveTM in all their 79 stores across Western Canada.

V-LoveTM will soon be available to the consumer in all London Drug Stores across Western Canada. Our first shipment to the London Drugs main distribution facility in Richmond, BC has been received.

V-LoveTM will also be available at Londondrugs.com online store for shipping across Canada.


Click Image To View Full Size

“We are very pleased to be working with London Drugs, a respected community leader and name synonymous with consumer products,” stated President Robert McAllister.

About London Drugs

Founded in 1945, B.C.-based London Drugs has 79 stores in more than 35 major markets throughout British Columbia, Alberta, Saskatchewan and Manitoba, including its online store www.londondrugs.com, London Drugs offers consumers a range of products from digital cameras and cosmetics to computers and televisions. Renowned for its creative approach to retailing, the company employs more than 7,500 people with pharmacy and health care services being the heart of its business. Committed to innovation and superior customer service, London Drugs has established itself as a reputable and caring company and continues to position itself for future growth and development.

About Enertopia

We are a company with the mission to empower people with a better way of living through healthy lifestyle choices in helping you live your life your way. Our core values of honesty, integrity, and commitment help to define our corporate practices and demonstrate our dedication in helping individuals whether they are encountering health issues based on age, diet or have suffered a traumatic physical, mental or emotional event.

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President: (250) 765-6412

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation and sale of sexual creams and other items, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that V-Love TM will have any meaningful impact on the Company or the Company will be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Enertopia Provides Canadian Medical Marihuana Update

Posted by AGORACOM-JC at 11:00 AM on Friday, June 12th, 2015

  • Signed a binding LOI to sell its wholly owned sub Thor Pharma Corp along with the MMPR application number 10MMPR0610
  • Burlington MMPR license application will continue in the application process under new ownership
  • Joint Venture could receive up to $1,500,000 in milestone payments upon the Burlington facility becoming licensed under the MMPR program

VANCOUVER, BC / June 12 2015 – Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) announces updates with respect to the Burlington and The Green Canvas Joint Ventures.

Enertopia has signed a binding LOI to sell its wholly owned sub Thor Pharma Corp along with the MMPR application number 10MMPR0610. The Burlington MMPR license application will continue in the application process under new ownership. The Joint Venture could receive up to $1,500,000 in milestone payments upon the Burlington facility becoming licensed under the MMPR program. These monies would be split approximately 50% with Lexaria Corp. Subsequent with this deal the Burlington Joint Venture between Enertopia and Lexaria which was entered into on May 27, 2014 has been terminated due to the pending sale of the project. The Enertopia and Lexaria Master Joint Venture Agreement entered into on March 5, 2014 is still in good standing as both companies continue to look at synergistic opportunities to increase shareholder value.

After thorough examination of the Medical Marihuana industry in Canada and current participants within the sector, it is apparent that raising capital to push projects forward is not currently in the best interests of the Company. Therefore, the Company and The Green Canvas have mutually agreed to terminate their Joint Venture and 6,400,000 shares of Enertopia held in escrow with respect to The Green Canvas Joint Venture will be returned back to corporate treasury and cancelled.

Enertopia is and will continue to be an advocate for medical cannabis for patients and applauds the landmark Supreme Court of Canada ruling on June 11, 2015. This ruling upheld the rights of legal MMAR and MMPR medical cannabis patients in Canada. The unanimous ruling allows valid legal medical patients to choose how they want to administer medical cannabis by the method that is best suited to their medical condition and body absorption. This is looks to be a very positive development for the Canadian medical marihuana sector going forward, as the Federal Government will have to modify or implement a program for the administration of other forms of medical cannabis consumption.

Enertopia will continue to look for opportunities in the MMJ and other sectors that offer the best return for all stakeholders with the least amount of dilution to the Company. The Company looks forward to utilizing its learned knowledge in the MMJ sector and will continue on its path of becoming a licensed producer.

“The Company has completed two milestones in building a stable foundation with its ownership of 1,000,000 shares in Lexaria Corp which has just filed PCT for patent pending bio technologies and the potential of approximately $750,000 in future payments from the Burlington application,” Stated President Robert McAllister

The Company looks forward to providing information via social media, website and press releases as news and events become known over the coming weeks.

About Enertopia

We are a company with the mission to empower people with a better way of living through healthy lifestyle choices in helping you live your life your way. Our core values of honesty, integrity, and commitment help to define our corporate practices and demonstrate our dedication in helping individuals whether they are encountering health issues based on age, diet or have suffered a traumatic physical, mental or an emotional event.

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President: (250) 765-6412

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation and sale of sexual creams and other items, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Company will receive any milestone payments from the sale of Thor Pharma and the Burlington MMPR application, or that the 1,000,000 shares of Lexaria Corp will have any meaningful impact on the Company or the Company will be able to obtain future financings or a license under the MMPR program.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Lexaria Intellectual Property Update

Posted by AGORACOM-JC at 8:24 AM on Friday, May 15th, 2015


KELOWNA, BC / May 15, 2015 / Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) provides the following update and information regarding its patent-pending technology; how it relates to the delivery of certain active ingredients such as CBD and THC, and how it relates also to market demand.

Lexaria has caused to be filed on April 28, 2015 and May 14, 2015, the latest in a line of provisional patent applications with the United States Patent and Trademark Office regarding its technology that were originally filed beginning in June, 2014. Lexaria’s new patent-pending technology is directed to food and beverage compositions infused with cannabinoids – e.g., THC and/or CBD – that provide enhanced cannabinoid oral bioavailability. We expect the United States Patent and Trademark Office to publish our provisional patent applications roughly in December 2015.

Lexaria’s proprietary process infuses lipids within foods and beverages with cannabinoids and produces compositions with synergistically enhanced cannabinoid absorption and bioavailability. The cannabinoid infused food and beverage compositions have the added benefit of masking the inherent unpleasant taste of cannabinoids to allow for better patient compliance with therapeutically administered cannabinoids.

It is important to understand certain facts:

Smoked or inhaled cannabinoids have reported bioavailabilities ranging from 2-56%, with an average of about 30% (Huestis (2007) Chem. Biodivers. 4:1770-1804; McGilveray (2005) Pain Res. Manag. 10 Suppl. A:15A – 22A). This variability is mainly due to differences in smoking dynamics. Cannabinoids that are absorbed through the mucous membranes in the mouth (buccomucosal application) have bioavailabilities of around 13% (Karschner et al. (2011) Clin. Chem. 57:66-75). By contrast, when cannabinoids are ingested, bioavailability is typically reduced to about 6% (Karschner et al. (2011) Clin. Chem. 57:66-75).

Lexaria’s patent-pending cannabinoid lipid-infusion technology is based in part on the goal of achieving much higher cannabinoid bioavailability than conventional means of oral cannabinoid ingestion.

Oral bioavailability into or approaching the range typical of smoked or inhaled cannabinoids would be potentially disruptive to the entire medical marijuana sector because it would offer patients an efficient option to reduce or even eliminate the need for smoking or inhalation delivery while simultaneously improving conventional edible cannabinoid formats.

To this end, the Company will undertake certain laboratory testing in the coming months to further characterize potentially transformative aspects of the technology and will report the outcome upon completion.

Benefits of the patent-pending technology, include:

1) A positive social health outcome through reduction of smoking of cannabinoids;
2) Improved confidence in consistent delivery of THC or CBD through oral ingestion;
3) Lower cost to consumers relative to conventional edible formats through higher rate of active ingredient delivery;
4) Easy and convenient active ingredient delivery through many readily available common everyday foods;
5) A disruptive competitive advantage for Lexaria versus any company that delivers THC or CBD through any other format, including traditional smoking.

By their nature, new inventions are unpredictable and not always entirely understood in advance. Many complex technologies are being pursued by the broader food and drug industries in relation to more effective delivery of drugs and other ingredients because their traditional oral bioavailability may be poor. Solid lipid nanoparticles, for example, have demonstrated improvements in bioavailability of some Class II, III, and IV drugs as much as 2-25 fold as seen below:

“The US FDA recommended high fat meals for food-effect studies because such fatty meals (800-1000 cal, 50%-65% fat, 25%-30% carbohydrates and 15%-20% proteins) affect GI physiology and maximize drug transfer into the systemic circulation.” (Food and Drug Administration, Guidance for industry: food-effect bioavailability and fed bioequivalence studies, food and drug administration. www.fda.gov)

Maximizing bioavailability is a common aim throughout the food, pharmaceutical and drug industries since efficiencies in delivering active ingredients also deliver many benefits.

About Lexaria

Lexaria is a food sciences company focused on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technologies. www.lexariaenergy.com

About ViPova(TM)

ViPova(TM) uses only legal hemp oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. There is no assurance that patent-pending applications will result in granted patents, or that competing companies, in their normal course of business, might not introduce other unrelated inventions superior to the Company’s own. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Lexaria’s ViPova(TM) Tea Available Soon at Amazon.com

Posted by AGORACOM-JC at 8:32 AM on Wednesday, April 8th, 2015

KELOWNA, BC / ACCESSWIRE / April 8, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) is very pleased to announce that ViPova(TM) tea will soon be available for sale at Amazon.com and other online retailers.

“We expect to have ViPova tea available for sale at the world’s largest online superstore,” said Lexaria CEO Chris Bunka. “We know we need to make our products more widely available and we couldn’t be more proud than to start at the top, with the world’s best online retailer.”

Small businesses like ViPova, world-class retail brands, and individual sellers increase their sales and reach new customers by leveraging the power of the Amazon.com e-commerce platform. Amazon.com strives to be Earth’s most customer-centric company and serves consumers through a focus on vast selection, price, and convenience. At peak times, Amazon USA sells as many as 426 items per second, or 36.8 million items in a single day. Some reports have indicated that 80-90 million Americans shop at Amazon.com every month. During 2014, Amazon.com reported full year revenue of approx. $88.9 Billion.

Although not available at Amazon today, Lexaria believes it is important to provide disclosure regarding this important pending development as it would mark a potentially significant new sales channel, and availability at Amazon.com should be imminent. Lexaria continues to open sales channels for its ViPova (TM) brand, making progress consistently as to the number of online locations where consumers can access our premium products. These efforts are ongoing and beginning to be productive.

As well, Lexaria has awarded an initial 6-month Search Engine Optimization (SEO) contract designed to increase the visibility of its online brands and support its online retailers and sellers. This SEO contract has already commenced and is expected to provide steadily improved visibility in the months to come, and will be part of our growing efforts to build brand recognition and interest in our products.

Vipova(TM) encourages other retailers, either online or brick-and-mortar, that wish to carry our ground-breaking products to contact us by email at customerservice@vipova.com for distribution information.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for opportunities that could provide potential above-market returns. www.lexariaenergy.com

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.

Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.